País: Irlanda
Língua: inglês
Origem: HPRA (Health Products Regulatory Authority)
Etoricoxib
KRKA, d.d., Novo mesto
M01AH; M01AH05
Etoricoxib
30 milligram(s)
Film-coated tablet
Product subject to prescription which may be renewed (B)
Coxibs; etoricoxib
Marketed
2016-11-25
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ETORICOXIB KRKA 30 MG FILM-COATED TABLETS ETORICOXIB KRKA 60 MG FILM-COATED TABLETS ETORICOXIB KRKA 90 MG FILM-COATED TABLETS ETORICOXIB KRKA 120 MG FILM-COATED TABLETS etoricoxib READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Etoricoxib Krka is and what it is used for 2. What you need to know before you take Etoricoxib Krka 3. How to take Etoricoxib Krka 4. Possible side effects 5. How to store Etoricoxib Krka 6. Contents of the pack and other information 1. WHAT ETORICOXIB KRKA IS AND WHAT IT IS USED FOR WHAT IS ETORICOXIB KRKA Etoricoxib Krka contains the active substance etoricoxib. Etoricoxib Krka is one of a group of medicines called selective COX-2 inhibitors. These belong to a family of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). WHAT IS ETORICOXIB KRKA USED FOR? Etoricoxib Krka helps to reduce the pain and swelling (inflammation) in the joints and muscles of people 16 years of age and older with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and gout. Etoricoxib Krka is also used for the short term treatment of moderate pain after dental surgery in people 16 years of age and older. WHAT IS OSTEOARTHRITIS? Osteoarthritis is a disease of the joints. It results from the gradual breakdown of cartilage that cushions the ends of the bones. This causes swelling (inflammation), pain, tenderness, stiffness and disability. WHAT IS RHEUMATOID ARTHRITIS? Rheumatoid arthritis is a long term inflammatory di Leia o documento completo
Health Products Regulatory Authority 28 January 2022 CRN00CS5N Page 1 of 14 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Etoricoxib Krka 30 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 30 mg etoricoxib. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet (tablet) White or almost white, round (diameter: 6 mm), slightly biconvex, film coated tablets with beveled edges. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Etoricoxib Krka is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis. Etoricoxib Krka is indicated in adults and adolescents 16 years of age and older for the short-term treatment of moderate pain associated with dental surgery. The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risks (see sections 4.3, 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1). _Osteoarthritis _ The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. _Rheumatoid arthritis _ The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient has clinically stabilized, a dose reduction to 6 Leia o documento completo